Compositions, Methods, and Kits for Eliciting an Immune Response

• US 20110142874A1
• Filed: 06/09/2009
• Published: 06/16/2011
• Est. Priority Date: 06/09/2008
• Status: Abandoned Application

• Current Assignee: Arizona Board of Regents (University of Arizona)
• Original Assignee: Arizona Board of Regents (University of Arizona)
• Inventors: Kibler, Karen, Huynh, Trung, Jacobs, Bertram
• Application Number:
  US12/996,942
• Publication Number:
  US 20110142874A1
• Time in Patent Office: Days
• US Class Current: 424/193.1
• CPC Class Codes: A61K 2039/55561 CpG containing adjuvants; Oligonucleotide containing adjuvants
• CPC Class Codes: A61K 2039/6031 Proteins
• CPC Class Codes: A61K 2039/62 characterised by the link between antigen and carrier
• CPC Class Codes: A61K 2039/625 binding through the biotin-streptavidin system or similar
• CPC Class Codes: A61K 39/0013 Therapeutic immunisation against small organic molecules, e.g. cocaine, nicotine
• CPC Class Codes: A61K 39/385 Haptens or antigens, bound to carriers

Abstract

The present invention relates to compositions, methods, and kits for eliciting an immune response to at least one antigen, in particular for enhancing antigen immunogenicity.

Claims

1. A conjugate comprising at least one antigen or small molecule conjugated to at least one polypeptide capable of binding a double-stranded polynucleotide, wherein the conjugate is able to elicit an immune response against the antigen or small molecule.

2. The conjugate of claim 1, wherein the double-stranded polynucleotide comprises a double-stranded polyribonucleotide (dsRNA).

3. The conjugate of claim 1, wherein the at least one polypeptide capable of binding a double-stranded polynucleotide comprises a binding domain of a protein selected from the group consisting of:

ADAR1, ZBP1, PKR-like kinase, and E3L.

4. The conjugate of claim 1 wherein the double stranded polyribonucleotide (dsRNA) comprises a first ligand.

5. The conjugate of claim 4 wherein the first ligand is biotin.

6. The conjugate of claim 4 further comprising a second ligand capable of binding to the first ligand.

7. The conjugate of claim 6 wherein the second ligand is a multimer, capable of binding more than one first ligand.

8. The conjugate of claim 7 wherein the second ligand comprises a tetrameric avidin.

9. The conjugate of claim 7 further comprising at least one adjuvant and/or at least one TLR agonist having a third ligand bound thereto, wherein the at least one adjuvant and/or at least one TLR agonist binds to the second ligand through interaction of the third ligand with the second ligand, and wherein the second ligand further binds to the dsRNA through interaction of the first and second ligand.

10. The conjugate of claim 9 wherein the first ligand comprises biotin and the second ligand comprises a tetrameric avidin, and wherein the third ligand comprises a biotin.

12. The conjugate of claim 9 wherein the at least one TLR agonist is selected from the group consisting of a TLR 4 agonist, a TLR9 agonist, a TLR 5 agonist, and a TLR 7/8 agonist.

13. The conjugate of claim 9 wherein the TLR agonist is selected from the group consisting of LPS, unmethylated CpG DNA, resiquimod and flagellin.

14. The conjugate of claim 1, wherein the at least one polypeptide comprises a Z-alpha domain or a variant thereof.

15. The conjugate of claim 1, wherein the at least one antigen is a disease-associated antigen.

16. A composition comprising the conjugate of claim 1 and a pharmaceutically acceptable carrier.

17. A DNA or RNA molecule encoding the conjugate of claim 1.

18. A host cell comprising the DNA or RNA molecule of claim 17.

19. A method for eliciting an immune response to an antigen in a subject, the method comprising administering to the subject the composition according to claim 16.

20. The conjugate of claim 1 wherein the small molecule comprises cocaine and wherein the polypeptide comprises E3L.

21. The conjugate of claim 13 wherein the small molecule comprises cocaine, and wherein the polypeptide comprises E3L and wherein the TLR agonist comprise unmethylated CPG DNA.

11. The conjugate of claim 11 wherein the polypeptide comprises E3L.

22. A kit comprising

a) a polypeptide capable of binding a double-stranded polynucleotide;

b) a dsRNA labeled with a first ligand; and

c) a second ligand that is able to bind to the first ligand.

23. The kit of claim 22 wherein the first ligand comprises biotin and the second ligand comprise a tetrameric avidin.

24. The kit of claim 22 further comprising at least one adjuvant and/or TLR agonist comprising a third ligand wherein the third ligand is able to bind the second ligand.

25. The kit of claim 24 wherein first ligand comprises biotin and the second ligand comprises tetrameric avidin and the third ligand comprises biotin.